Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial (Q38522489)

3 September 2017

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial (English)

1 reference

intermittent claudication

3 September 2017

1 reference

1 reference

11

Brian H Annex

1 reference

3 September 2017

Robert J Lederman

1

1 reference

3 September 2017

Farrell O Mendelsohn

2

1 reference

3 September 2017

R David Anderson

3

1 reference

3 September 2017

Jorge F Saucedo

4

1 reference

3 September 2017

Alan N Tenaglia

5

1 reference

3 September 2017

James B Hermiller

6

1 reference

3 September 2017

William B Hillegass

7

1 reference

3 September 2017

Krishna Rocha-Singh

8

1 reference

3 September 2017

Thomas E Moon

9

1 reference

3 September 2017

M J Whitehouse

10

1 reference

3 September 2017

TRAFFIC Investigators

12

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

3 September 2017

1 reference

3 September 2017

359

1 reference

3 September 2017

9323

1 reference

3 September 2017

2053-2058

1 reference

Update on Some Epidemiologic Features of Intermittent Claudication: The Framingham Study

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Medical treatment of peripheral arterial disease and claudication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Therapeutic angiogenesis in ischemic limbs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Basic fibroblast growth factor induces angiogenesis in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

What is meant by intention to treat analysis? Survey of published randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

European multicenter study on propionyl-L-carnitine in intermittent claudication.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908937-7

7 January 2021

10.1016/S0140-6736(02)08937-7

Identifiers

DOI

1 reference

3 September 2017

1 reference